Key result
GMT-transduced cardiac mesenchymal cells modestly improved global left ventricular contractility and reduced regional myocardial collagen deposition compared to control cells in a rat model of ischemic cardiomyopathy.
Why the study?
Whether and how intrinsic cardiogenic factor expression in donor cells contributes to their cardiac reparative capacity in cell therapy remained largely ambiguous.
Does intramyocardial injection of GMT-transduced CMCs improve cardiac function and reduce fibrosis in a rat model of chronic ischemic cardiomyopathy?
Does intramyocardial injection of GMT-transduced CMCs improve cardiac function and reduce fibrosis in a rat model of chronic ischemic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Enhancing cardiomyogenic lineage commitment in cardiac mesenchymal cells via GMT expression augments anti-fibrogenic paracrine signaling and modestly improves left ventricular contractility in ischemic cardiomyopathy.
Intrinsic cardiogenic factor expression, a proxy for cardiomyogenic lineage commitment, may be an important determinant of donor cell cardiac reparative capacity in cell therapy applications; however, whether and how this contributes to their salutary effects remain largely ambiguous. Methods: The current study examined the consequences of enhanced cardiogenic factor expression, via lentiviral delivery of GMT (GATA4, MEF2C, and TBX5), on cardiac mesenchymal cell (CMC) anti-fibrogenic paracrine signaling dynamics, in vitro, and cardiac reparative capacity, in vivo. Proteome cytokine array analyses and in vitro cardiac fibroblast activation assays were performed using conditioned medium derived from either GMT-or GFP control-transduced CMCs, to respectively assess cardiotrophic factor secretion and anti-fibrogenic paracrine signaling aptitude. Results: Relative to GFP controls, GMT CMCs exhibited enhanced secretion of cytokines implicated to function in pathways associated with matrix remodeling and collagen catabolism, and more ably impeded activated cardiac fibroblast Col1A1 synthesis in vitro. Following their delivery in a rat model of chronic ischemic cardiomyopathy, conventional echocardiography was unable to detect a therapeutic advantage with either CMC population; however, hemodynamic analyses identified a modest, yet calculable supplemental benefit in surrogate measures of global left ventricular contractility with GMT CMCs relative to GFP controls. This phenomenon was neither associated with a decrease in infarct size nor an increase in viable myocardium, but with only a marginal decrease in regional myocardial collagen deposition.
No takes yet. Share an insight, caveat, or question.
Heidel et al. (2020) studied Chronic ischemic cardiomyopathy (n=31). GMT-transduced cardiac mesenchymal cells (GMT CMCs) vs. GFP-transduced CMCs (GFP CMCs) or vehicle (PBS) was evaluated on Maximal rate of developed LV pressure (dP/dtmax) in mmHg/sec (p=<0.05). GMT-transduced cardiac mesenchymal cells modestly improved global left ventricular contractility and reduced regional myocardial collagen deposition compared to control cells in a rat model of ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: